Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H18N6O5S2 |
Molecular Weight | 462.503 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(CSC3=CN=NN3)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C4=CC=C(O)C=C4)C(O)=O
InChI
InChIKey=UOCJDOLVGGIYIQ-PBFPGSCMSA-N
InChI=1S/C18H18N6O5S2/c19-12(8-1-3-10(25)4-2-8)15(26)21-13-16(27)24-14(18(28)29)9(7-31-17(13)24)6-30-11-5-20-23-22-11/h1-5,12-13,17,25H,6-7,19H2,(H,21,26)(H,28,29)(H,20,22,23)/t12-,13-,17-/m1/s1
DescriptionCurator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81027 and http://www.ncbi.nlm.nih.gov/pubmed/426514
Curator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81027 and http://www.ncbi.nlm.nih.gov/pubmed/426514
Cefatrizine is a broad-spectrum, semisynthetic, first-generation cephalosporin with antibacterial activity. Cefatrizine binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Cefatrizine is used to treat a large variety of bacterial infections, such as respiratory tract, ear, skin and urinary tract infections. Cefatrizine is less effective against gram positive bacteria than first generation drugs. Antibiotics require constant drug level in body for therapeutic effect.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5026 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26776155 |
|||
Target ID: Bacterial growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/1137381 |
|||
Target ID: map00550 Sources: http://www.kegg.jp/dbget-bin/www_bget?D02406 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
[Infective pathogens and drug resistance in burned patients]. | 2003 Aug |
|
Simultaneous determination of cefatrizine and clavulanic acid in dog plasma by HPLC. | 2004 Apr 1 |
|
European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe. | 2006 Aug |
|
Synthesis, characterization, antibacterial and anti-inflammatory activities of enoxacin metal complexes. | 2009 |
|
Antibiotic Treatment of Dogs and Cats during Pregnancy. | 2010 Dec 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://en.pharmacodia.com/web/drug/1_10470.html
Curator's Comment: Can also be administered i.v. http://www.ncbi.nlm.nih.gov/pubmed/6660858
It is given by mouth as the base or, more commonly, as a compound with propylene glycol, in usual doses equivalent to 500 mg twice daily of cefatrizine.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/426514
Curator's Comment: Bacterial isolates were from urine, sputum, throat, stool, and wound cultures of
patients. Cefatrizine inhibited the majority of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella at concentrations below 12.5 mug/ml.
A total of 90% of isolates were inhibited by 1.6 ug of cefatrizine per ml
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01DB07
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
||
|
WHO-VATC |
QJ01DB07
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CEFATRIZINE
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
DB13266
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
100000092004
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
529
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
DTXSID7022752
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
D002436
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
2179
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1095284
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
SUB07376MIG
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
m3187
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
6410758
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
8P4W949T8K
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
257-324-2
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
C81027
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
51627-14-6
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
3839
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY